Research programme: FibroKine biomimetic peptides - CSL Behring/University of Pittsburgh
Alternative Names: IP-10pLatest Information Update: 28 May 2022
At a glance
- Originator University of Pittsburgh
- Developer CSL Behring; University of Pittsburgh
- Class Antifibrotics; Chemokines; Peptides; Peptidomimetics
- Mechanism of Action Angiogenesis inhibitors; Chemokine modulators; CXCR3 receptor agonists; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Pulmonary fibrosis
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Fibrosis in USA
- 28 Feb 2022 No recent reports of development identified for research development in Pulmonary-fibrosis in USA (Inhalation)